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SUMMARY  
Background: To compare pterygium recurrence after 
bare sclera excision with and without topical 
lodoxamide. 
Design: Randomised double-blind study.  
Methods: The study involved 61 patients with primary 
pterygia who had bare sclera excision after informed 
consent. They were post-operatively treated by either 
of 2 treatment groups for 4 weeks, with a 30-months 
follow-up: Controls/placebo = Guttae prednisolone 1% 
with chloramphenicol 0.5% plus guttae distilled water. 
Test group = Guttae prednisolone 1% with 
chloramphenicol 0.5%  plus guttae lodoxamide 0.1%.  
Results: Sixty patients were analysed. Control Group 
had 20 females and 10 males, aged 28-69.5 years, 
mean 42.0(± 10.9). Test Group had 15 males and 15 
females, aged 17-75 years, mean 46.0(±12.6). 
Recurrence for the Test Group was 11(37%) within 30 
months and 11(37%) for the Control Group within 30 
months (OR=1.00, CI: 0.35-2.858). Main 
complications encountered were granuloma: 7(11.7%) 
from the controls and 5(8.3%) from the test group; 
restriction in the motility of medial rectus muscle: 
1(1.7%) from each group; persistent vascularisation at 
site of excision: 1(1.7%) from each group and 
adherence leukoma with uveitis 1(1.7%) from the 
control group, the latter also had persistent peripheral 
corneal epithelial defect later resulting in a dellen. No 
significant difference was found between the treatment 
groups with respect to recurrence, type and time of 
complications, orientation and morphology of 
pterygium, P>0.05.  
Conclusion: The recurrence of pterygium is high 
(about one third) with or without the use of adjuvant 
lodoxamide. 
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Pterygium is a degenerative, benign, fibrovascular 
growth, which extends from the conjunctiva into the 
cornea. Treatment is surgical but high recurrences rates 
are primarily seen after bare sclera surgery, 24% to 
over 80%.1-4 The quest to reduce these unacceptable 
high rates of recurrence associated with bare sclera 
surgery have led to various adjuvants being used over 
the years. These include B-radiation with Strontium-90 
given recurrence rates of 0.5- 20%, 5,6 
chemotherapeutic agents such as mitomycin-C, 0-
38%,7-9 and conjunctival autograft, 2-39%. 1,2,9,10 
Conjunctival autograft results in remarkably few 
complications but B-radiation and the 
chemotherapeutic agents such as mitomycin-C have 
potentially more serious complications such as cataract, 
aseptic necrosis of the sclera and cornea, with attendant 
perforation, severe intraocular inflammation and 
infection.7,11-13  
 
Some studies, using histology and 
immunohistochemistry, have demonstrated the 
presence of mast cells and eosinophils in excised 
pterygia (both primary and recurrent types). These 
findings have suggested that an immunologic 
mechanism or allergy, possibly of Types 1, 3 and 4 
hypersensitivity, may contribute to the pathogenesis of 
pterygium.14-17 In addition, the type of mast cells found 
in both primary and recurrent pterygia have been found 
to be tryptase-positive, chymase- positive mast cells, a 
finding also seen in active vernal conjunctivitis and 
giant papillary conjunctivitis, both with immune based 
pathogenesis.17, 18   
 
These findings suggest that anti-allergic drugs such as 
Lodoxamide, which act as mast cells stabiliser 
inhibiting in vivo Type 1 immediate hypersensitivity 
reaction,19 and Olopatadine, a relatively selective H1-
receptor antagonist and inhibitor of histamine release 
from the mast cells,20 may help to reduce recurrence.  
 
 







Other factors implicated in the pathogenesis of 
pterygium include ultraviolet rays and dusty 
environment,21 conditions which are prevalent in 
tropical countries like Ghana.  Pterygium is very 
common in Ghana and the surgical procedure 
commonly performed is excision using bare sclera 
technique. Anecdotal observation has shown both 
successes and recurrences after long-term follow up in 
years. In recent years, the use of some of the adjuvants 
to bare sclera surgery, such as conjunctival autografts 
and antimetabolites, by some ophthalmologists in 
Ghana have been on the increase. There has not been 
any published data in the literature from Ghana on the 
recurrence rate of pterygium after bare sclera excision 
with adjuvant treatment. The study therefore aimed at 
comparing recurrence rate of bare sclera technique with 
and without post-operative adjuvant lodoxamide eye 
drops in Ghanaians.  
 
MATERIALS AND METHODS 
Patients undergoing surgical treatment for primary 
pterygium were assessed for eligibility into a 
prospective, randomised-double blind study. Sixty-one 
of these patients who satisfied the inclusion criteria 
were admitted into the study, after obtaining ethical 
clearance from the University of Ghana Medical 
School Ethics and Protocol Review Committee. The 
study was completed in the year 2004. 
 
The sample size was calculated based on recurrence 
estimates for bare sclera technique of 30% which falls 
within those reported in the literature ranging from 24 -
80%3-6 at 95% confidence levels and 80% statistical 
power (1-β). This gave us a sample estimate of 32 per 
group. Patients were eligible if they had a primary 
pterygium with neither external eye pathology nor 
previous eye surgery. Only those who gave consent 
were recruited. The history and examination of all the 
patients were obtained through a structured 
questionnaire. The history included; occupation 
(outdoor or indoor), use of spectacles, allergy or atopy, 
and any other ocular disease.  
 
Complete ocular examination noted the gross features 
of the pterygia (fleshy (vascularised), intermediate, or 
atrophic) based on the translucency of the pterygium, 
presence or absence of calcification, its laterality 
(unilateral or bilateral), location (nasal, temporal or 
kissing), its extent into cornea and encroachment on the 
visual axis. The morphology of the pterygium was 
classified as: 
 T1 – transparent/ atrophic  
 T2 -  intermediate  
 T3 -  fleshy  
 
Excision of pterygium 
All the patients had retrobulbar anaesthesia with 
xylocaine/adrenaline 2%, and measurement of the 
dimensions of the pterygia done intra-operatively using 
callipers and a 4x Loop. Excision of the pterygium was 
by the bare sclera technique, in which the head of the 
pterygium was detached from the cornea by careful 
superficial keratectomy with number 15 scapel blade, 
and a triangular excision of the rest of the pterygium 
with overlying conjunctiva and underlying tenons, 
leaving a bare sclera of about 5mm from the limbus.  
 
Haemostasis was achieved, where necessary, by 
pressure padding.  Chloramphenicol ointment and 
guttae homatropine 2% were instilled immediately and 
the eye padded overnight. Postoperatively, from day 
after surgery till four (4) weeks, patients were grouped 
and treated by either 1 or 2 treatment below in a 
random, double masked way: Group.1= Guttae 
prednisolone 1% with chloramphenicol 0.5%  q.i.d. 
plus guttae distilled water (placebo) t.i.d. Group. 2 = 
Guttae prednisolone 1% with chloramphenicol 0.5% 
q.i.d. plus guttae lodoxamide 0.1% three times daily. 
 
All surgeries were performed by the same surgeon on 
outpatient basis. All excised tissues were sent for 
histopathological confirmation of pterygium. 
Recurrence was diagnosed when a fibrovascular 
growth occurred, in the position of the previously 
excised pterygium, crossing the limbus and extending 
onto the cornea for any distance. Postsurgical 
conjunctival granulomas were left untreated and all 
disappeared within one month. 
 
Treatment concealment 
The drugs, except the lodoxamide were produced and 
bottled by the Drug Manufacturing Unit of the hospital, 
which relabelled all 4 drugs according to the treatment 
groups above, concealing their names. 
 
Patients’ allocation and randomization 
An independent person using systematic random 
sampling did the allocation of the patients. Group 
membership was determined by randomly selecting the 
first person’s group by toss of a coin. The subsequent 
persons were alternately assigned their groups.  
 
For those with bilateral pterygia, and also kissing 
pterygia, the eye or the orientation of the pterygium to 
be enrolled in the study was predetermined at the 
beginning of the study for all patients, by tossing a 
coin, resulting in all right eyes and in the case of 
kissing pterygia, nasal type being selected for 
 
 







inclusion. Patients were evaluated post-operatively on 
days 1 and 8, then 1 month, 3, 6, 12, 18, 24 and 30 
months thereafter. The group code was opened at the 
end of the 30 months. 
 
Statistical analysis 
Data was captured using Microsoft Office Excel and 
analysed using SPSS Version 16.0. Continuous 
numerical data was captured as Mean and Standard 
deviation (SD) and categorical data as percentages (%).  
Chi-square test was used to compare proportions and 
student T-test used to compare means. Correlation 
analysis was used to establish linear associations for 
scale and ordinal variable while regression and logistic 
regression was employed to establish causal 
associations in the data. Odds ratio was used to 





A total number of 61 patients were enrolled but data 
for 60 patients were analysed, 30 in each treatment 





Figure 1 Diagram showing the flow of participants 
through each stage of study 
 
Figure 1 shows the flow of patients through each stage 
of the study and Table 1 gives the clinical features of 
the 2 groups.  
 
 
Treatment Group 1(Control/Placebo) had 20 females 
and 10 males, aged 28-69.5 years, Mean 42.0(± 10.9). 
Treatment Group 2 had 15 males and 15 females, aged 
17-75 years, Mean 46.0(±12.6).  
 
There was no statistical difference between the 2 
treatment groups with respect to gender	 (p=0.295)	
and	age	 p> 0.05. 
 
There was no statistical difference between the 2 
treatment groups with respect to type and time of 
complications, recurrence (time and rate), laterality, 
orientation and morphology of pterygium, P>0.05. 






















Out of 30 patients in each group, 11 (36.7%) had 
recurrence respectively. The Odds ratio, OR, for the 2 
groups = 1.00 (CI: 0.35-2.858). The mean time of 
recurrence for the control group was 4.5(± 2.2) months, 
while that of the test group was 4.1(±1.8) months, 
p>0.05. The overall recurrence time showed a bimodal 
pattern at 3months: 10(45.0%) and at 6 months: 
7(31.8%) (Figure 2)  
 
Complications 
Main complications encountered were granuloma: 
7(11.7%) from the controls and 5(8.3%) from the test 
group; restriction in the motility of medial rectus 
muscle: 1(1.7%) from each group; persistent 
vascularisation at site of excision: 1(1.7%) from each 
group and adherence leukoma with uveitis 1(1.7%) 
from the control group, the latter also had persistent 
peripheral corneal epithelial defect for about 2 weeks 































No significant difference was found between the two 
groups with regards to complications encountered, 
p=0.51. Table 1 
 
Table 1  Clinical features of patients with pterygia. 
Characteristics ControlGP 
(1) , N (%) 
Treatment 












4 (22%)  
0.277 
 
















 10 (16.7) 
20 (33.3) 
1.00 












































T1 – transparent/ atrophic; T2 - moderately 
vascularised / fleshy; T3 - more vascularised / fleshy.  





Figure 3 Duration of follow-up in Control and 
Treatment Groups 
 
One patient who had persistent headaches, ocular 
irritation as well as redness with the use of one 
treatment was taken out of the study and referred to an 
ophthalmologist for treatment. His group code was the 
test treatment group (code broken at the end of the 
study).  
Patients were followed up for up to 30 months (Group 
1 for 1-30 and group 2 for 1-24 months), p> 0.05, with 
progressively significant numbers being lost to follow 
up after 6 months (Figure 3).   
 
DISCUSSION 
This study showed no advantage of lodoxamide in 
preventing recurrence of pterygium. There was no 
statistically significant difference between the 2 
treatment groups with respect to recurrence, type and 
time of complications, gender, age, laterality, 
orientation and morphology of pterygium. The overall 
recurrence (37%) and intra-group recurrences (37%) 
were high.. 
 
The bare-sclera technique, used alone as a method of 
treatment for pterygium, is associated with high 
recurrence rates. This is as compared to other forms of 
surgical treatment (such as conjunctival autograft, 
amniotic membrane graft and lamellar corneal 
transplants) or adjuvant treatments (such as beta 
irradiation, thiotepa and intra- and post-operative 
mytomycin-C).3,7,11-13,22-24 
Although bare sclera excision is a commonly 
performed surgical procedure by ophthalmologists in 
Ghana, there is no published data from  the country 
which has looked at the recurrence rate of bare sclera 
pterygium excision with adjuvant treatment. Hence, no 
comparison could be made with this study. 
 
The high recurrence rates in this study (37%) could be 
partly explained by the fact that the patients involved in 
this study continued to be exposed to abundant ultra-
violet rays and dust for most times of the year. This is 
because although  majority had indoor occupations, 
they continued to live in Ghana. Majority of the 
recurrences occurred within 6 months post-operative. 
This early recurrence in the first year post surgery 
supports other published data.25 The number of 
recurrences reduced thereafter.which could be due to 
the progressively high number lost to follow up after 6 
months [Figure 3].  
 
Ibechukwu in Jos, Nigeria had prospectively compared 
the effect of post-operative use of antibiotics, steroids 
and sodium cromoglycate (another mast cell stabiliser), 
after pterygium excision. He found sodium 
cromoglycate to be most effective in controlling 
pterygium recurrence, reducing it to 20% relative to 
53.1% and 35.1% for the antibiotic and steroid groups 
respectively.13 This study, however, did not find any 
difference in recurrence between the lodoxamide and 
the control groups.  
 
 







This finding may corroborate findings from other 
studies, which have suggested that the type and 
increase in mast cells found in primary and recurrent 
pterygia were tryptase-positive, chymase- positive mast 
cells. The contribution of this type of mast cells to the 
pathogenesis of pterygium may not be immune 
system–related but may rather function through 
angiogenesis and tissue remodelling mechanism.15, 26 
This calls for further studies. 
 
 Additional data on quantification of mast cells with 
histochemistry or immunohistochemistry in both 
groups would have added value to the study. The 
strength of this study, however, is that it is the first 
randomised, double-masked study to determine the 
recurrence rate of pterygium excision with bare sclera 
technique with or without an adjuvant treatment in 
Ghanaians. This information, hopefully, would form a 
baseline for comparison with future studies within the 
same population. Such future studies may explore other 
effective, evidence-based forms of treatment (surgery 
with adjuvant treatments) for reducing the high 
recurrence rate associated with excision of pterygium. 
This is necessary since pterygium is a disease which is 
very common and is an important cause of ocular 
irritation and cosmetic disfigurement in the Ghanaian 
population. Finally, the finding should reinforce the 
need to completely abandon bare sclera technique 
alone as a surgical procedure for pterygium in Ghana. 
 
CONCLUSION 
In conclusion, the post-excision recurrence of 
pterygium is high (about one third) with or without the 
use of adjuvant lodoxamide. 
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